A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women receive an RSV vaccine during their third ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Residents in public residential aged care services aged 60 and over can now claim a free vaccine for Respiratory Syncytial ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu immunizations in 2025. The panel voted to expand RSV protection for infants ...

Nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or nirsevimab during the first season those products were available, according to ...

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

In this article, we identify the top 10 most impactful articles for pediatric hospital medicine in 2025, as presented at the Pediatric Update at SHM Converge 2025 in Las Vegas. Four publications are ...

It was approved in early June, making it the second FDA-approved RSV preventive therapy for young children. The first, AstraZeneca’s Beyfortus (nirsevimab-alip), received FDA approval in July ...

The guideline also addresses the role of nirsevimab, a long-acting monoclonal antibody. Recent data shows that nirsevimab reduces RSV-related hospitalizations by up to 90% in infants.